AI‑augmented TB drug pipelines expose systemic gaps in funding, global health equity, and R&D coordination
Original framing: “Tuberculosis drug discovery gets smarter with AI” — Phys.org
Machine‑learning models trained on large‑scale phenotypic screens have demonstrably reduced false‑positive rates in TB compound selection, accelerating lead optimisation. However, reproducibility hinges on open data standards, rigorous validation across multiple Mycobacterium tuberculosis strains, and transparent algorithmic provenance.
AI is reshaping TB drug discovery, yet its promise is entangled with historic patterns of neglect, inequitable financing, and cultural blind spots.
By weaving indigenous pharmacological wisdom, cross‑cultural health practices, and participatory governance into the AI pipeline, we can break the cycle of techno‑centric hype and build a resilient, equitable drug development ecosystem. Concrete actions—global pooled funds, open‑source AI co‑creation, traditional knowledge integration, and IP reform—must be coordinated by WHO, national health ministries, and community stakeholders. Only through such systemic alignment can new TB therapies move from algorithmic prediction to accessible treatment for the world’s most vulnerable populations.